Articles

Ublituximab plus TGR-1202 in Heavily Pretreated and High-Risk CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ibrutinib in Relapsed/Refractory CLL After Allogeneic Stem-Cell Transplant

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Dinaciclib plus Ofatumumab in Patients with Relapsed/Refractory CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ibrutinib versus Ofatumumab in Patients with Relapsed/Refractory CLL in the RESONATE Study

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

The FCR2 Regimen: A Phase 2 Study of FCR-Lite and Lenalidomide in Frontline CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Idelalisib plus Rituximab for Relapsed CLL: Interim Analysis in Subpopulations with del17p and Other Adverse Prognostic Factors

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

The RESONATE-17 Trial: Efficacy and Safety of Ibrutinib in Patients with Relapsed/Refractory CLL and del17p

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Interim Analysis of Phase 2 ICLL01: Ofatumumab and High-Dose Methylprednisolone in Patients at Highest Risk for Relapsed/Refractory CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

ONO-4059: A New Oral, Selective BTK Inhibitor for Patients with High-Risk CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Results from the CLL11 Study: Salvage Therapy with Obinutuzumab plus Chlorambucil in Patients with CLL and Comorbidities

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Page 206 of 329